

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/BEEEBA18D2DEN.html>

Date: August 2019

Pages: 88

Price: US\$ 3,500.00 (Single User License)

ID: BEEEBA18D2DEN

Abstracts

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

SUMMARY

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.

The molecules developed by companies in Phase II, Preclinical and Discovery stages

are 4, 8 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase 0 and Preclinical stages comprises 1, 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Bladder Cancer, Melanoma, Prostate Cancer, Autoimmune Disorders, Bone Metastasis, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Colon Carcinoma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma and Solid Tumor.

Furthermore, this report also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)

The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects

The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development

Biomics Biotechnologies Co Ltd

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

IMV Inc

MimiVax LLC

Optimum Therapeutics LLC

Oxford Vacmedix UK Ltd

Polyplus-Transfection SA

Stemline Therapeutics Inc

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles

Antibody to Target Survivin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress**Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****BGA-005 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****BI-1361849 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****BKM-1644 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****BKM-1740 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****DPX-Survivac - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****FL-118 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****MV-2C2 - Drug Profile****Product Description****Mechanism Of Action****R&D Progress**

MX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OVM-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UC-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Autoimmune Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Colon Carcinoma and Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Neuroblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target BIRC5 for Relapsed Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor

Survivin or BIRC5) - Discontinued Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones

Featured News & Press Releases

Jun 12, 2019: New Phase 2 clinical trial results continue to demonstrate potential clinical benefit of IMV's DPX-survivac in combination with Merck's Keytruda in patients with DLBCL

Jun 04, 2019: IMV to provide update on phase 2 clinical results with Merck Keytruda in DLBCL by means of conference Call and Webcast

Jun 01, 2019: Phase II trial shows favorable response for patients receiving combination therapy with SurVaxM

Jun 01, 2019: Imv presents new positive data from phase 2 monotherapy arm of its decide1 trial in advanced ovarian cancer and continued duration of clinical benefits to patients with progression free survival

May 16, 2019: IMV to present new data at 2019 ASCO annual meeting from its Phase 2 clinical trial evaluating DPX-Survivac in Ovarian Cancer

Apr 18, 2019: IMV to provide updated clinical data at 2019 ASCO annual meeting on lead candidate DPX-Survivac in Ovarian Cancer and other solid tumors

Mar 26, 2019: Initial phase 2 data from an IMV clinical study continues to demonstrate DPX-Survivac's prior trend as a potential monotherapy treatment for advanced ovarian cancer

Jan 29, 2019: IMV announces clinical update for DPX-Survivac program in ovarian cancer following positive feedback from U.S. FDA

Dec 13, 2018: IMV presents updated positive data from phase 1b/2 combination clinical trial in advanced ovarian cancer at 2018 ESMO Immuno-Oncology Congress

Dec 10, 2018: IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac's Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018

Nov 28, 2018: Brain Cancer Immunotherapy SurVaxM extends survival, even in hard-to-treat patients

Nov 22, 2018: IMV amends Phase Ib/II trial of recurrent ovarian cancer drug

Nov 16, 2018: Stemline Therapeutics announces oral presentation of SL-701 phase 2 data in second-line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)

Oct 16, 2018: Stemline Therapeutics announces SL-701 clinical data to be featured, including an Oral Presentation, at upcoming ESMO 2018 Congress

Sep 18, 2018: IMV announces early positive results from phase 2 clinical trial of lead candidate DPX-Survivac in combination with Merck's Keytruda in patients with DLBCL

Appendix

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Biomics Biotechnologies Co Ltd, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Canget BioTekpharma LLC, H2 2019
Pipeline by IMV Inc, H2 2019
Pipeline by MimiVax LLC, H2 2019
Pipeline by Optimum Therapeutics LLC, H2 2019
Pipeline by Oxford Vacmedix UK Ltd, H2 2019
Pipeline by Polyplus-Transfection SA, H2 2019
Pipeline by Stemline Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Biomics Biotechnologies Co Ltd

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

IMV Inc

MimiVax LLC

Optimum Therapeutics LLC

Oxford Vacmedix UK Ltd

Polyplus-Transfection SA

Stemline Therapeutics Inc

I would like to order

Product name: Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/BEEEBA18D2DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BEEEBA18D2DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970